Lennox-Gastaut Syndrome

1. Disease Information

Overview. Lennox-Gastaut Syndrome is a severe, childhood-onset developmental and epileptic encephalopathy (DEE) defined by a triad: 1. Multiple seizure types — obligatorily including tonic seizures (the hallmark, often nocturnal) plus atypical absences, atonic/drop attacks, and frequently myoclonic, generalized tonic-clonic, and nonconvulsive status epilepticus; 2. A characteristic EEG signature — diffuse slow spike-and-wave complexes (<2.5–3 Hz) in the awake state and bursts of generalized paroxysmal fast activity (GPFA, ~10–20 Hz) during sleep (GPFA is considered the electrographic correlate of tonic seizures and is near-specific for LGS); 3. Cognitive and behavioral impairment — intellectual disability that is usually progressive.

Seizures are characteristically drug-resistant, and the encephalopathy is lifelong. The 2022 ILAE syndrome classification for the first time laid down formal diagnostic criteria, which matters because the older literature is muddied by inconsistent inclusion definitions.

Key identifiers (⚠️ verify against OAK/OLS before curation — several are heterogeneous): - MONDO: MONDO:0016532 (Lennox-Gastaut syndrome) — verify in local sqlite:obo:mondo per the new-MONDO-term cache-miss memory note. - OMIM: 606369 is cross-referenced by GARD/Orphanet, but note that the live OMIM entry 606369 currently carries the title "Macrocephaly and Epileptic Encephalopathy" — OMIM does not maintain a single clean LGS phenotype entry because the syndrome is genetically heterogeneous. Individual genetic causes have their own DEE MIM numbers. Treat the OMIM mapping as soft. - Orphanet: ORPHA:2382 (confirmed). - ICD-10: G40.812 / G40.813 (intractable, with/without status epilepticus). ICD-11: 8A62.1 (approximate — verify). - MeSH: D065768 (Lennox Gastaut Syndrome). UMLS: C0520725.

Synonyms / alternative names: Lennox syndrome; Lennox-Gastaut-Dravet (obsolete lumping); "epileptic encephalopathy with slow spike-wave"; historically overlapped with "petit mal variant" and "childhood epileptic encephalopathy." It is distinct from — but often evolves out of — West syndrome / infantile spasms.

Data provenance. Information here is overwhelmingly disease-level aggregated (OMIM, Orphanet, ILAE consensus, systematic reviews, RCTs) rather than individual-patient/EHR. The main EHR-derived signals are the mortality and healthcare-utilization linkage cohorts (e.g., the German claims study).

2. Etiology

LGS is etiologically heterogeneous — the defining feature of the whole entry. Broadly, causes split into identifiable (symptomatic/secondary, ~65–75%) and unknown/cryptogenic (~25–35%, shrinking as genetic testing improves).

Disease causal factors (upstream tributaries): - Structural (the largest identifiable bucket): hypoxic-ischemic encephalopathy, cortical malformations (focal cortical dysplasia, lissencephaly, polymicrogyria, tuberous sclerosis tubers, hypothalamic hamartoma), congenital infections, stroke, trauma, tumors. - Genetic: de novo dominant variants in a long list of DEE genes (see §4). Over 900 monogenic causes of DEEs have been catalogued. - Metabolic/mitochondrial: inborn errors that present as DEE. - Prior epileptic encephalopathy: roughly 10–30% of LGS evolves from West syndrome/infantile spasms — a developmental trajectory rather than an independent cause.

Risk factors: - Genetic: a de novo pathogenic variant in an intolerant DEE gene (SCN2A, STXBP1, CHD2, GABRB3, ALG13, SCN8A, DNM1, etc.). Mostly not "susceptibility loci" in the GWAS sense — these are high-penetrance dominant lesions. - Environmental/perinatal: perinatal hypoxia, prematurity, CNS infection (meningitis/encephalitis), traumatic brain injury in early childhood. - Demographic: age (onset window 1–8 yr, peak 3–5), male sex (modest male predominance), and a prior history of infantile spasms.

Protective factors. No established genetic or dietary protective factors specific to LGS. The nearest analogues are treatment-induced (early seizure control, avoidance of seizure-aggravating drugs). Note: sodium-channel blockers such as carbamazepine, oxcarbazepine, phenytoin, and vigabatrin can worsen myoclonic/absence seizures in LGS — an "anti-protective" iatrogenic factor worth capturing.

Gene-environment interactions. Not well characterized as formal GxE. The relevant interaction is developmental-timing × lesion: the same structural or genetic insult produces LGS specifically when it perturbs the maturing thalamocortical network in the early-childhood window; the identical genotype/lesion at another age yields a different syndrome. This "network maturation state" gating is the closest thing to a GxE story.

3. Phenotypes

LGS is defined by its phenotype cluster. For each, HP-term suggestions and typical characteristics:

Core seizure phenotypes: | Phenotype | HPO suggestion | Notes / frequency | |---|---|---| | Seizures (overall) | HP:0001250 | ~100% (defining) | | Tonic seizures | HP:0032792 | Obligatory hallmark; often nocturnal; ~present in nearly all | | Atypical absence seizures | HP:0007270 | Very frequent (~60–90%) | | Atonic/astatic (drop) seizures | HP:0010819 | Frequent; cause injurious falls | | Myoclonic seizures | HP:0032794 / HP:0001336 | Common | | Generalized tonic-clonic seizures | HP:0002069 | Common | | Nonconvulsive status epilepticus | HP:0002133 (status epilepticus) | Occurs in ~50–75% at some point | | Falls / drop attacks | HP:0002527 | Major morbidity driver |

EEG phenotypes: - Generalized slow spike-and-wave (<2.5–3 Hz): HP:0010845 (EEG with generalized slow spike-and-wave complexes). - Generalized paroxysmal fast activity in sleep: closest is HP:0011198 / HP:0011197 (EEG with generalized epileptiform discharges) — no precise GPFA HP term exists; flag as an ontology gap. - Abnormally slow background rhythm.

Cognitive/behavioral phenotypes: - Intellectual disability: HP:0001249 (progressive; often severe by adolescence). - Global developmental delay: HP:0001263 (frequently precedes/accompanies onset). - Cognitive regression/plateau: HP:0100543 (cognitive impairment). - Behavioral abnormality: HP:0000708; autistic behavior HP:0000729; aggression HP:0000718; ADHD-like inattention/hyperactivity HP:0007018. - Sleep disturbance (recently reviewed as a major, under-recognized burden).

Phenotype characteristics: - Onset: childhood, typically 3–5 yr (range 1–8); onset before age 1 is atypical. - Severity: moderate-to-severe and largely fixed/progressive for cognition; seizure severity fluctuates but is chronically drug-resistant. - Progression: cognitive trajectory is progressive/regressive; seizure semiology evolves with age (tonic seizures may become more prominent in adolescence/adulthood; absences and drops may attenuate). - Frequency among affected: tonic seizures and cognitive impairment approach 100% (definitional); other seizure types are variably present.

Quality-of-life impact. Substantial and multidimensional — injurious drop attacks (fractures, dental/facial trauma, need for helmets), high caregiver burden, dependency, institutionalization risk, sleep disruption, and behavioral comorbidity. Systematic reviews (Orphanet J Rare Dis 2023) document heavy healthcare utilization and among the lowest QoL scores in pediatric epilepsy.

4. Genetic / Molecular Information

Framing: there is no single "LGS gene." LGS is a phenotypic convergence point; genetic testing yields a molecular diagnosis in a substantial minority, mostly de novo dominant variants.

Landmark evidence — the Epi4K exome study (Allen et al., Nature 2013, PMID: 23934111 ✅ verified): whole-exome trio sequencing of 264 probands (149 infantile spasms + 115 LGS) found de novo mutations enriched in genes intolerant to variation, with genome-wide-significant associations for GABRB3 and ALG13. De novo mutations were seen in ≥15% of the cohort.

Causal / recurrently implicated genes (de novo dominant unless noted): - Ion channels (channelopathies): SCN1A, SCN2A, SCN8A, KCNQ2, KCNA2, KCNT1, CACNA1A, HCN1. - GABA-A receptor subunits: GABRB3, GABRA1, GABRG2 — directly implicate inhibitory neurotransmission. - Synaptic / vesicle-trafficking (synaptopathies): STXBP1, DNM1, IQSEC2. - Neuronal migration / cortical development: DCX, FLNA, ARX, LIS1(PAFAH1B1). - mTOR pathway: MTOR, TSC1/TSC2 (tuberous sclerosis), DEPDC5. - Chromatin / epigenetic regulators: CHD2 (≥11 de novo variants reported in DEE incl. LGS), plus others. - Glycosylation / metabolic: ALG13, SLC25A39, and others. - Additional single-case reports (e.g., TANC2 truncating variant, PMID from 2021 case report; NRG2, DNAJC5).

Variant characteristics: - Classification: pathogenic/likely pathogenic per ACMG/AMP (check ClinVar/ClinGen per gene). - Type: predominantly missense and protein-truncating (nonsense/frameshift/splice); also copy-number/structural (via chromosomal microarray). - Allele frequency: de novo variants are absent from population databases (gnomAD) — that absence is part of their pathogenicity argument. - Origin: overwhelmingly germline de novo (arising in parental gametes/early embryo); not inherited in most cases — key genetic-counseling point. - Functional consequence: mixed — loss of function (GABRB3, STXBP1, DNM1, CHD2 haploinsufficiency), gain of function (some SCN2A/SCN8A), and dominant-negative (some GABA-A subunit variants). The GABRB3 N328D knock-in mouse (PMC10179596) is a functional model that reproduces an LGS-like phenotype.

Modifier genes: not systematically defined; the genetic background modulating penetrance/expressivity is an open question.

Epigenetic information: CHD2 (chromodomain helicase) links LGS to chromatin remodeling dysregulation; broader disease-specific methylation signatures are not established. (Search-first: ENCODE, Roadmap.)

Chromosomal abnormalities: chromosomal microarray detects pathogenic CNVs in a subset; large structural lesions and ring chromosome 20 are associated with LGS-like phenotypes (ring 20 classically mimics LGS with nonconvulsive status).

Suggested GO/gene annotations: GABA signaling GO:0007214; regulation of GABAergic synaptic transmission GO:0032228; synaptic vesicle exocytosis GO:0016079; sodium ion transmembrane transport GO:0035725; potassium ion transmembrane transport GO:0071805; neuron migration GO:0001764; TOR signaling GO:0031929; chromatin remodeling GO:0006338. HGNC IDs to bind (lowercase hgnc: per repo convention): SCN2A, STXBP1, CHD2, GABRB3, SCN8A, DNM1, KCNQ2, MTOR, ALG13, etc.

5. Environmental Information

• Environmental factors: perinatal hypoxia-ischemia is the most important; also CNS infection (bacterial meningitis, viral encephalitis), traumatic brain injury, and any early-childhood cortical insult. No specific toxin/pollutant is causally established.
• Lifestyle factors: not applicable as causes (this is a pediatric encephalopathy); relevant lifestyle domain is management — sleep hygiene, seizure-trigger avoidance, and dietary therapy (§12).
• Infectious agents: not a primary infectious disease, but congenital/early CNS infections are among the acquired structural causes. Some cases follow encephalitis. No single pathogen is definitional. (NCBI Taxonomy: not applicable as a defining agent.)

6. Mechanism / Pathophysiology

The unifying model — secondary network epilepsy. The convergent-endpoint view (Archer/Warren and colleagues; Front Neurol 2014, PMID: 24902608; Neurology 2019 "The epileptic network of LGS") holds that regardless of the initiating lesion, LGS manifests through a distributed thalamocortical–brainstem network whose stereotyped failure produces the slow spike-wave and tonic phenomena.

Causal chain (trigger → manifestation): 1. Initiating insult (structural lesion, de novo channel/synaptic/chromatin variant, prior IS) perturbs the developing cortex. 2. Aberrant network maturation — failure of normal synaptic pruning → cortical hyperconnectivity and pathological network behavior; excitation/inhibition imbalance from GABAergic/glutamatergic dysfunction. 3. Secondary bilateral synchrony — focal/multifocal cortical hyperexcitability recruits the whole network, generating generalized slow spike-wave and GPFA discharges. This is why a focal cortical lesion can produce a "generalized"-looking syndrome, and why removing that lesion can abolish the whole process. 4. Thalamus as synchronizer/amplifier, not initiator — EEG-fMRI shows interictal discharges activate brainstem and centromedian/anterior thalamic nuclei; the prefrontal/premotor and frontoparietal association cortices are the peak hubs (bilateral premotor cortex / caudal middle frontal gyrus per fMRI; frontoparietal FDG-PET hypometabolism). This is the rationale for thalamic (centromedian) closed-loop and DBS neuromodulation (Brain Communications 2024, fcae161). 5. Clinical output — multiple generalized seizure types + progressive encephalopathy from chronic network disruption during a critical developmental period.

Molecular pathways / cellular processes: - GABAergic inhibition failure (GABRB3/GABRA1/GABRG2; GABA-A receptor CHEBI:16865 GABA) → reduced inhibitory tone. - Ion-channel dysfunction (SCN2A/SCN8A Nav, KCNQ2/KCNA2/KCNT1 Kv/KNa) → altered GO:0042391 regulation of membrane potential and neuronal firing. - Synaptic vesicle/exocytosis defects (STXBP1, DNM1) → impaired GO:0007268 chemical synaptic transmission. - mTOR hyperactivation (TSC/MTOR) → dysplastic, hyperexcitable cortex (GO:0031929). - Chromatin dysregulation (CHD2) → altered neurodevelopmental gene expression.

Protein dysfunction: loss of function (haploinsufficiency of GABRB3/STXBP1/CHD2), gain of function (Nav channels), dominant-negative (some GABA-A subunits). (UniProt/AlphaFold for structural detail.)

Metabolic changes: frontoparietal glucose hypometabolism on FDG-PET is a robust network signature; specific inborn errors underlie the metabolic-etiology subset. The ketogenic diet's efficacy implicates cerebral energy metabolism shift toward ketone utilization as a therapeutic lever.

Immune involvement: not a primary immune-mediated epilepsy; neuroinflammation is a general seizure-associated process, not a defining mechanism.

Cell types / anatomy (for annotation): - Cell types (CL): neuron CL:0000540, GABAergic interneuron CL:0000617, glutamatergic/pyramidal neuron CL:0000598/CL:0000679, thalamocortical projection neurons. - Anatomy (UBERON): brain UBERON:0000955, cerebral cortex UBERON:0000956, frontal lobe UBERON:0001870, thalamus UBERON:0001897, brainstem UBERON:0002298, corpus callosum UBERON:0002336. (Centromedian thalamic nucleus may lack a precise UBERON term — flag.)

Molecular profiling / advanced tech: most mechanistic traction is from EEG-fMRI, FDG-PET, and network connectivity rather than omics; single-cell/spatial transcriptomic LGS-specific data are sparse. GABRB3 N328D knock-in mice provide the cleanest functional-genomics model.

7. Anatomical Structures Affected

• Organ level: brain (primary); nervous system is the sole primary system. Secondary/whole-body effects are consequences of drops (musculoskeletal injury) and chronic disability (respiratory — aspiration; nutritional).
• Body systems: central nervous system primarily; secondary musculoskeletal (fall injuries), respiratory (aspiration pneumonia, a leading cause of death), and psychiatric/behavioral.
• Tissue/cell level: cortical gray matter (association cortex), thalamic nuclei, brainstem; affected populations are cortical/thalamic neurons and GABAergic interneurons (CL:0000617).
• Subcellular level (GO Cellular Component): synapse GO:0045202, presynaptic/postsynaptic membranes, ion-channel complexes at the plasma membrane, synaptic vesicle GO:0008021.
• Localization: bilateral, diffuse but frontally/frontoparietally predominant; the network is bilateral and largely symmetric (secondary bilateral synchrony), even when the initiating lesion is unilateral/focal.

8. Temporal Development

• Onset: pediatric, typically ages 1–8 (peak 3–5); insidious/subacute, often emerging after or alongside developmental delay, sometimes evolving from West syndrome (~10–30%).
• Progression / stages: early phase (emerging multiple seizure types + slowing EEG) → established phase (full triad, tonic seizures dominant, cognitive regression) → adult phase (seizures persist; semiology shifts, tonic seizures and status remain; drops/absences may lessen).
• Course: chronic, lifelong, drug-resistant; not relapsing-remitting — persistent with fluctuating seizure burden.
• Remission: spontaneous remission is rare (~80–90% continue to have seizures into adulthood). Treatment reduces but rarely abolishes seizures.
• Critical period: the early-childhood developmental window is both the vulnerability window and the intervention window — early seizure control is thought to matter for developmental outcome, though drug resistance blunts this.

9. Inheritance and Population

Epidemiology (from Sullivan et al. systematic review, Epilepsia 2024, and burden-of-illness reviews): - Incidence: ~14.5–28 per 100,000 (context-dependent — some figures are cumulative childhood incidence, interpret carefully). - Prevalence: ~5.8–60.8 per 100,000 for probable LGS; ~2.9–28 per 100,000 for narrow/confirmed definitions. Enriched in intellectual-disability populations (~7%, up to ~16% institutionalized). - LGS accounts for 1–4% of all childhood epilepsy but ~10% of epilepsy with onset before age 5.

Genetic epidemiology: - Inheritance pattern: predominantly sporadic / de novo dominant; not classically Mendelian-inherited. A minority reflect inherited structural/metabolic conditions (e.g., tuberous sclerosis = AD; some X-linked genes ALG13, IQSEC2, CDKL5, DCX, FLNA). - Penetrance/expressivity: de novo DEE variants are generally high-penetrance but variably expressive (same gene → different DEE syndromes). - Anticipation: not applicable (not a repeat-expansion disorder). - Germline mosaicism: possible (relevant to recurrence-risk counseling) but low recurrence overall. - Founder effects / consanguinity / carrier frequency: generally not applicable given the de novo/sporadic nature; consanguinity matters only for the rare AR metabolic causes.

Demographics: - Sex ratio: modest male predominance (boys > girls). - Ethnicity/geography: no established ethnic or geographic predilection. - Age distribution: childhood-onset with a lifelong prevalent adult population (survivors persist into adulthood).

10. Diagnostics

Diagnosis is electroclinical — the ILAE 2022 criteria formalize it.

Core diagnostic tests: - EEG (defining): interictal slow spike-and-wave <2.5–3 Hz on a slow background; sleep-activated generalized paroxysmal fast activity (GPFA), the near-specific correlate of tonic seizures. Ictal EEG for tonic/atonic/atypical-absence events. (LOINC: EEG panels.) - Video-EEG / prolonged monitoring to capture the multiple seizure types. - Brain MRI: to identify structural etiology (malformations of cortical development, hypoxic injury, tubers). (RadLex/Radiopaedia.) - FDG-PET: frontoparietal hypometabolism (supportive/network, not diagnostic).

Etiologic workup (genetic testing): - Chromosomal microarray (CMA) for CNVs; karyotype/FISH for ring chromosome 20 and other structural anomalies. - Epilepsy gene panels / whole-exome sequencing (WES) — highest yield; trio WES best for de novo detection. Whole-genome sequencing (WGS) increasingly used. - Metabolic workup / mitochondrial testing when metabolic etiology suspected. - GeneReviews / GTR / ClinGen for gene-level interpretation.

Clinical criteria: ILAE 2022 syndrome definition requires the seizure-type + EEG + cognitive triad, with tonic seizures and/or GPFA carrying strong diagnostic weight.

Differential diagnosis (key mimics to rule out): - Epilepsy with myoclonic-atonic seizures (Doose syndrome) — myoclonic-atonic predominant, better prognosis, no tonic seizures/GPFA. - Dravet syndrome — SCN1A, fever-sensitive, earlier onset. - Atypical benign partial epilepsy / pseudo-Lennox — better outcome. - Ring chromosome 20 epilepsy, continuous spike-wave in slow sleep (CSWS), West syndrome (may precede LGS).

Screening. No population newborn screen for LGS itself; relevant genetic causes may surface on expanded newborn screening or carrier screening only for the specific metabolic/monogenic subset.

11. Outcome / Prognosis

• Prognosis is unfavorable but variable. ~80–90% continue to have seizures into adulthood; cognitive impairment is usually permanent and often progressive.
• Mortality: significantly elevated vs. general population. A German linkage cohort reported ~2.88% mortality over 10 years vs. ~0.01% in age-matched controls — an ~orders-of-magnitude excess. Causes include SUDEP (sudden unexpected death in epilepsy), status epilepticus, aspiration pneumonia, and injury from drop attacks.
• Morbidity/disability: severe — intellectual disability, dependency, injurious falls, behavioral comorbidity, high institutionalization rate. Among the highest disability burdens in pediatric epilepsy (GBD/ICF framing).
• Prognostic factors (worse outcome): early onset, evolution from West syndrome, symptomatic/structural etiology, high tonic-seizure and status frequency, early cognitive impairment. Cryptogenic cases with later onset and no prior IS tend to fare relatively better.
• QoL measures: disease-specific and generic tools (caregiver-reported) consistently show low scores; drop-seizure frequency is a key modifiable QoL driver (hence trial endpoints focus on drops).

12. Treatment

Goal: seizure-burden reduction (especially injurious drops) and QoL — not cure. Polytherapy is the norm; drug resistance is expected.

Pharmacotherapy — FDA-approved for LGS (8 agents; approval years): clonazepam (1975), felbamate (1993), lamotrigine (1998), topiramate (2001), rufinamide (2008), clobazam (2011), cannabidiol (2018), fenfluramine (2022). Valproic acid is common first-line broad-spectrum background therapy (widely used, not LGS-labeled).

Landmark trial evidence (verified): - Cannabidiol (Epidiolex), CHEBI:69478 — GWPCARE4 (Thiele et al., Lancet 2018, PMID: 29395273 ✅) and GWPCARE3 (Devinsky et al., NEJM 2018, PMID: 29768152 ✅): add-on CBD significantly reduced drop-seizure frequency vs. placebo; 2024 consensus panel (Epilepsia Open) optimizes dosing. Modality: SMALL_MOLECULE (phytocannabinoid). - Fenfluramine (Fintepla), CHEBI:5000 — Knupp et al., JAMA Neurol 2022;79(6):554–564, PMID: 35499850 ✅ verified: RCT, n=263; 0.7 mg/kg/d gave 26.5% median drop-seizure reduction vs. 7.6% placebo (P=.001); no valvular heart disease or pulmonary hypertension observed. Open-label extension (Knupp, Epilepsia 2023, PMID: 36196777 ✅) confirmed durable benefit. - Rufinamide, CHEBI:32219 — pivotal RCT (Glauser et al., Neurology 2008) established efficacy for drop attacks. ⚠️ PMID from memory ~18936427/18401024 — verify with just fetch-reference before curation. - Lamotrigine — Motte et al., NEJM 1997. ⚠️ Verify PMID. - Felbamate — Felbamate Study Group, NEJM 1993 (efficacy strong but limited by aplastic anemia/hepatotoxicity risk). ⚠️ Verify PMID. - Topiramate — Sachdeo et al., Neurology 1999. ⚠️ Verify PMID. - Clobazam, CHEBI:31401 — Ng et al., Neurology 2011 (pivotal). ⚠️ Verify PMID.

Emerging / off-label pharmacotherapy: - Cenobamate — retrospective/real-world adult and pediatric LGS series show meaningful drop-seizure reduction and enable clobazam dose reduction (PMC9821211, PMC12255617, 2023–2024). Not yet LGS-labeled. - Soticlestat (CH24H inhibitor) — phase-3 signal in LGS was a nonsignificant numerical reduction in drops (contrast with positive Dravet data); development context evolving. - Low-dose fenfluramine in adults (PMC12317795, 2024). - 2024 consensus treatment algorithm published (Epilepsy & Behavior, S1525-5050(24)00643-7).

Pharmacogenomics: relevant at the drug-safety level — e.g., HLA-linked risk for lamotrigine cutaneous reactions (SJS/TEN); CYP-mediated clobazam metabolism (CYP2C19). Emerging precision therapy matches the molecular etiology to mechanism (e.g., sodium-channel-blocker avoidance in some, targeted approaches for mTOR/GABA-A variants). (IJMS 2025 precision-therapeutics review, PMC12025602.)

Non-pharmacologic / interventional: - Ketogenic diet (MAXO:0000088 dietary intervention as fallback term; check for a specific MAXO ketogenic term): ~50% of patients achieve >50% seizure reduction; some >90%. - Vagus nerve stimulation (VNS): ~50% responder rate (>50% reduction), improving over time; palliative. - Corpus callosotomy (MAXO:0000004 surgical procedure): most effective option for injurious drop attacks — disconnects interhemispheric spread. Systematic review/meta-analysis supports callosotomy + diet efficacy (Child's Nerv Syst 2021). - Thalamic (centromedian) DBS / closed-loop stimulation: emerging neuromodulation targeting the network hub (Brain Communications 2024). - Resective surgery when a focal structural lesion drives the network. - Supportive/rehabilitative: helmets for drop protection, PT/OT/speech (MAXO:0000950 supportive care; NCIT:C15315 rehabilitation), behavioral and sleep management.

Advanced therapeutics (experimental): gene-targeted/ASO approaches are on the horizon for specific monogenic causes (STXBP1, SCN2A, etc.) but not yet LGS-syndrome therapies. ClinicalTrials.gov (e.g., NCT03936777 fenfluramine long-term safety) for active programs.

MAXO/NCIT term suggestions: pharmacotherapy NCIT:C15986 (with therapeutic_agent CHEBI drugs); dietary intervention MAXO:0000088; surgical procedure MAXO:0000004; supportive care MAXO:0000950; genetic counseling MAXO:0000079. VNS and ketogenic-diet-specific MAXO terms should be looked up with OAK.

13. Prevention

• Primary prevention: limited — reduce acquired causes via good perinatal care (preventing hypoxic-ischemic injury), CNS-infection prevention/vaccination, and TBI prevention. No vaccine or lifestyle intervention prevents LGS directly.
• Secondary prevention: early recognition and control of infantile spasms/West syndrome may reduce evolution to LGS (an active hypothesis and management priority); early EEG in a child with developmental delay + new seizures for prompt diagnosis.
• Tertiary prevention (complication avoidance): the practical core — drop-injury prevention (helmets, callosotomy), SUDEP-risk mitigation (seizure control, nocturnal monitoring), aspiration/nutrition management, avoiding seizure-aggravating ASMs (carbamazepine, oxcarbazepine, phenytoin, vigabatrin).
• Genetic counseling (MAXO:0000079): for families with an identified de novo variant, recurrence risk is generally low (low-level germline mosaicism caveat); for inherited causes (TSC, X-linked genes) counseling is more consequential. Prenatal/preimplantation testing applies only when a specific familial variant is known.
• Screening: no population screen; cascade/prenatal testing only for the monogenic/structural subset.

14. Other Species / Natural Disease

• Taxonomy: LGS as a defined electroclinical syndrome is essentially human-specific (NCBITaxon:9606). There is no recognized naturally occurring LGS in other species (OMIA has no LGS entry).
• Comparative biology: the mechanisms are conserved — epilepsy and the underlying channel/synaptic genes have clear orthologs. Mouse models of specific genes (GABRB3, SCN2A, etc.) recapitulate seizure/encephalopathy features but not the full human syndrome (human association-cortex network complexity isn't reproduced).
• Zoonotic potential: none (non-infectious, non-transmissible).

This section is largely N/A — LGS is a human network-epilepsy syndrome; the comparative angle lives entirely in the model-organism domain below.

15. Model Organisms

• Model types: predominantly mammalian (mouse) gene-specific models; also zebrafish for channel/high-throughput drug screening; iPSC-derived neurons/organoids for synaptic phenotyping; in vitro electrophysiology of variant channels/receptors.
• Genetic models: knock-in (point-mutation), knockout, and conditional/humanized alleles of DEE genes.
• Flagship example: GABRB3 N328D heterozygous knock-in mouse (PMC10179596) — reproduces an LGS-like phenotype (multiple seizure types, EEG abnormalities, behavioral/cognitive deficits), one of the better syndrome-level recapitulations. Other models: Scn2a, Scn8a, Stxbp1, Dnm1 (fitful mouse), Chd2, Cdkl5, Alg13 mice — each captures a slice of the phenotype.
• Phenotype recapitulation: single-gene models reproduce seizures, EEG discharges, and neurodevelopmental deficits, and are used for mechanism and drug testing. Limitation: none fully reproduces the human syndrome's distributed frontoparietal network dysfunction and cognitive regression — a HUMAN_MODEL_MISMATCH-flavored gap worth flagging in the KB (evidence exists in models but the network-level, association-cortex biology is human-specific).
• Applications: genotype-specific pathophysiology, ASM screening, precision-therapy proof-of-concept (e.g., gene-targeted approaches).
• Resources: MGI, IMPC/KOMP, ZFIN, Alliance of Genome Resources; Cellosaurus for iPSC lines.

Curation notes & caveats for the KB entry

• Evidence-source tagging: the RCTs (fenfluramine, CBD) are HUMAN_CLINICAL; the GABRB3 N328D mouse is MODEL_ORGANISM; variant-channel electrophysiology is IN_VITRO; network/PET modeling papers are HUMAN_CLINICAL or COMPUTATIONAL depending on method. Keep model-organism evidence distinct from human phenotype claims.
• Verified PMIDs (safe to seed): 23934111 (Epi4K), 35499850 (fenfluramine RCT), 36196777 (fenfluramine OLE), 29395273 (CBD GWPCARE4), 29768152 (CBD GWPCARE3), 24902608 (secondary network epilepsy).
• PMIDs to verify before use (from memory): the older ASM pivotal trials (rufinamide/Glauser, lamotrigine/Motte, felbamate, topiramate/Sachdeo, clobazam/Ng). Run just fetch-reference and confirm exact-quote snippets — don't trust my recalled numbers.
• Identifier flags: MONDO:0016532 (verify via local sqlite:obo:mondo; watch the OLS cache-miss issue), OMIM 606369 is a soft/heterogeneous mapping, ORPHA:2382 confirmed.
• Ontology gaps to note: no precise HP term for generalized paroxysmal fast activity; centromedian thalamic nucleus may lack a UBERON term; ketogenic-diet/VNS MAXO terms need OAK lookup.
• Module conformance opportunity: LGS is a natural conformer for epilepsy_excitation_inhibition_imbalance (key node #Excitation-Inhibition Imbalance) — the E/I-imbalance → hyperexcitability → seizure chain maps cleanly, with LGS substituting the secondary-bilateral-synchrony/thalamocortical-network specialization.

Primary sources drawn on: - Allen et al., De novo mutations in epileptic encephalopathies, Nature 2013 (PMID 23934111) - Knupp et al., Fenfluramine RCT in LGS, JAMA Neurol 2022 (PMID 35499850) - Knupp et al., Fenfluramine OLE, Epilepsia 2023 (PMID 36196777) - Thiele et al., Cannabidiol GWPCARE4, Lancet 2018 (PMID 29395273) - Devinsky et al., Cannabidiol GWPCARE3, NEJM 2018 (PMID 29768152) - Archer et al., LGS as secondary network epilepsy, Front Neurol 2014 (PMID 24902608) - Sullivan et al., Global epidemiology of Dravet & LGS, Epilepsia 2024 - Burden of illness in LGS systematic review, Orphanet J Rare Dis 2023 - Precision Therapeutics in LGS, IJMS 2025 (PMC12025602) - GABRB3 N328D knock-in mouse LGS model (PMC10179596) - Targeting thalamocortical circuits for closed-loop stimulation in LGS, Brain Commun 2024 - Orphanet: Lennox-Gastaut syndrome (ORPHA:2382) - Diagnosis of LGS and early recognition, Expert Rev Neurother 2024

That's the whole delta mapped — tributaries, the swampy convergence point, and the levees we've got to hold it back. The single most load-bearing idea for the KB is that "cause" and "syndrome" live at different altitudes here: curate the many upstream etiologies as distinct genetic/structural nodes, but let them all drain into the shared secondary-network-epilepsy mechanism. Want me to go ahead and scaffold the actual kb/disorders/Lennox-Gastaut_Syndrome.yaml entry from this, or run the MONDO/OMIM identifier verification first?